{
    "clinical_study": {
        "@rank": "131150", 
        "acronym": "PARIDOINAL2013", 
        "arm_group": [
            {
                "arm_group_label": "Paricalcitol", 
                "arm_group_type": "Experimental", 
                "description": "Paricalcitol oral capsules."
            }, 
            {
                "arm_group_label": "Calcifediol", 
                "arm_group_type": "Active Comparator", 
                "description": "Calcifediol oral drops."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate the superiority of paricalcitol treatment at\n      early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone)\n      compared to the use of vitamin D nutritional supplements (calcifediol) in patients with\n      renal transplantation."
        }, 
        "brief_title": "Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Secondary Hyperparathyroidism Due to Renal Causes", 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Secondary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient that have willingly signed and dated the ICD (Informed Consent Document)\n             approved by the EC (Ethics Committee) before any study procedure and after they have\n             been explained the study,  they have read the ICD and have had the opportunity to\n             make questions about it.\n\n          -  Patients of both genders and older than 18 years candidates to an immediately renal\n             transplantation from living or deceased donor.\n\n          -  24 hours previous to the transplantation, patient must have a significant grade of\n             secondary hyperparathyroidism, defined as iPTH levels between 250 and 600 pg/mL as\n             per central laboratory results.\n\n          -  Patients with a preformed antibody panel <20% 24 hours before the transplantation or\n             that are considered by the investigator of low immunological risk (PRA determination\n             is being done on local laboratory, not central).\n\n          -  Serum calcium (corrected by albumin) < 10 mg/dL 24 hour previous to the\n             transplantation as per central laboratory results.\n\n          -  Patients that are to be treated with immunosuppression based on tacrolimus, mofetil\n             mycofenolate or mycophenolic acid and with steroids and that are not going to be\n             treated with mTOR (mammalian target of rapamycin) inhibitors. Tacrolimus and steroids\n             must not be removed on the 6 month post-transplantation.\n\n          -  Patients that are able to take oral capsules on the first week post-transplantation.\n\n        Exclusion Criteria:\n\n          -  Third or subsequent renal transplantation.\n\n          -  Positive cross-match assay or ABO (A-B-0) incompatibility\n\n          -  Patients that have been or are going to be recipients of other organs other than the\n             kidney or a double kidney transplantation.\n\n          -  Patients with history of allergic reaction or sensibility to paricalcitol,\n             calcifediol or similar study drugs (related with vitamin D).\n\n          -  Patients with chronic gastrointestinal disease, that, based on investigators\n             criteria, can cause significant gastrointestinal malabsorption.\n\n          -  Patient with hypo or hyperthyroidism not controlled based on investigators criteria.\n\n          -  Patient with uncontrolled hypertension based on investigators criteria.\n\n          -  Patients that, 48 hours previous to transplantation, have been receiving\n             calcimimetics.\n\n          -  Patients with VIH (human immunodeficiency virus)infection of positive serology for\n             HBV (hepatitis B virus) and/or HCV (hepatitis C virus)\n\n          -  Patients on treatment with drugs  contraindicated with paricalcitol and calcifediol\n             (based on SMPC)\n\n          -  Patients that are participating on other clinical trial with investigational drugs.\n\n          -  Women of childbearing potential (defined as those whose last menstruation was <2\n             years ago and that are not surgically sterilized) that are not willing to use correct\n             contraception during study treatment.\n\n          -  Patient with other diseases or conditions that based on investigators criteria are\n             not suitable for the study.\n\n          -  Treatment will not be started if the Calcium-Phosphorus product (CAxP)is >55 mg2/dL2\n             or in case of hyperphosphatemia considered significant as per investigator criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939977", 
            "org_study_id": "ACA-SPAI-11-24", 
            "secondary_id": "2013-001326-25"
        }, 
        "intervention": [
            {
                "arm_group_label": "Paricalcitol", 
                "description": "1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.", 
                "intervention_name": "Paricalcitol", 
                "intervention_type": "Drug", 
                "other_name": "Zemplar"
            }, 
            {
                "arm_group_label": "Calcifediol", 
                "description": "5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.", 
                "intervention_name": "Calcifediol", 
                "intervention_type": "Drug", 
                "other_name": "Hidroferol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcifediol", 
                "Ergocalciferols"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Hyperparathyroidism", 
            "Hyperparathyroidism Secondary", 
            "Paricalcitol", 
            "Calcifediol", 
            "Parathyroid hormone", 
            "Renal transplantation"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "contact": {
                    "email": "rlauzurica.germanstrias@gencat.cat", 
                    "last_name": "Ricardo Lauzurica, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08916"
                    }, 
                    "name": "Hospital Universitari Germans Trias I Pujol de Badalona"
                }, 
                "investigator": {
                    "last_name": "Ricardo Lauzurica, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jmcruzado@bellvitgehospital.cat", 
                    "last_name": "Josep M Cruzado, Dr", 
                    "phone": "+34 93 2607602"
                }, 
                "facility": {
                    "address": {
                        "city": "L'Hospitalet de Llobregat", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08907"
                    }, 
                    "name": "Hospital Universitari de Bellvitge"
                }, 
                "investigator": {
                    "last_name": "Josep M Cruzado, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ruizjc@humv.es", 
                    "last_name": "Juan Carlos Ruiz Sanmill\u00e1n, Dr", 
                    "phone": "+34 94 202520"
                }, 
                "facility": {
                    "address": {
                        "city": "Santander", 
                        "country": "Spain", 
                        "state": "Cantabria", 
                        "zip": "39008"
                    }, 
                    "name": "Hospital Universitario Marqu\u00e9s de Valdecilla"
                }, 
                "investigator": {
                    "last_name": "Juan Carlos Ruiz Sanmill\u00e1n, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "atorres@ull.es", 
                    "last_name": "Armando Torres Ram\u00edrez, Dr", 
                    "phone": "+34 922 678000"
                }, 
                "facility": {
                    "address": {
                        "city": "San Cristobal de La Laguna", 
                        "country": "Spain", 
                        "state": "Las Palmas de Gran Canaria", 
                        "zip": "38320"
                    }, 
                    "name": "Complejo Hospitalario Universitario de Canarias"
                }, 
                "investigator": {
                    "last_name": "Armando Torres Ram\u00edrez, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Badajoz", 
                        "country": "Spain", 
                        "zip": "06080"
                    }, 
                    "name": "Hospital Infanta Cristina"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Fundaci\u00f3 Puigvert-Iuna"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Universitari Vall D'Hebron"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08003"
                    }, 
                    "name": "Hospital Del Mar"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "C\u00e1diz", 
                        "country": "Spain", 
                        "zip": "11009"
                    }, 
                    "name": "Hospital Puerta Del Mar"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "C\u00f3rdoba", 
                        "country": "Spain", 
                        "zip": "14004"
                    }, 
                    "name": "Hospital Reina Sof\u00eda"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Granada", 
                        "country": "Spain", 
                        "zip": "18014"
                    }, 
                    "name": "Hospital Universitario Virgen de Las Nieves"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Coru\u00f1a", 
                        "country": "Spain", 
                        "zip": "15006"
                    }, 
                    "name": "Complexo Hospitalario Universitario A Coru\u00f1a"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Hospital Ram\u00f3n Y Cajal"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "Domingohernandez@gmail.com", 
                    "last_name": "Domingo Hern\u00e1ndez Marrero, Dr", 
                    "phone": "+34 951 290000"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00e1laga", 
                        "country": "Spain", 
                        "zip": "29010"
                    }, 
                    "name": "Complejo Hospitalario Regional de M\u00e1laga"
                }, 
                "investigator": {
                    "last_name": "Domingo Hern\u00e1ndez Marrero, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41013"
                    }, 
                    "name": "Hospital Virgen Del Roc\u00edo"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "Hospital Universitari I Polit\u00e8cnic La Fe"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain", 
                        "zip": "50009"
                    }, 
                    "name": "Hospital Universitario Miguel Servet"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.", 
        "overall_contact": {
            "email": "jmcruzado@bellvitgehospital.cat", 
            "last_name": "Josep M Cruzado, Dr", 
            "phone": "+34 93 260 76 02"
        }, 
        "overall_contact_backup": {
            "email": "senefro.nieves@senefro.org", 
            "last_name": "Nieves Collantes", 
            "phone": "+34 902 92 92 10"
        }, 
        "overall_official": {
            "affiliation": "Fundaci\u00f3n SENEFRO - Hospital Universitario de Bellvitge - Barcelona.", 
            "last_name": "Josep M Cruzado, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percentage of patients with iPTH serum concentration >110 pg/mL post transplantation and 6 month after treatment.", 
            "measure": "Percentage of patients with iPTH serum concentration >110 pg/mL.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939977"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change on iPTH serum concentration on each treatment group 6 month post transplantation and treatment.", 
                "measure": "Change on iPTH serum concentration", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Percentage of patients with at least iPTH\u226530% of reduction from basal level.", 
                "safety_issue": "No", 
                "time_frame": "1, 3 and 6 months"
            }, 
            {
                "measure": "Percentage of patients that reach at least a 30% iPTH reduction at the end of the study.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Percentage of patients with iPTH levels between 70-110 pg/mL at the end of the study.", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "measure": "Percentage of patient with presence of calcifications on protocol renal biopsies at 6 months after treatment en each treatment group.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Incidence, compared and separate,  of each of the following events: acute rejection, acute rejection confirmed with biopsy and/or subclinic rejection and/or chronic damage.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Presence of alloreactive T memory cells against donor's antigen at 6 months after treatment en each treatment group.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change on concentration of bone markers (alkaline phosphatase and osteocalcin) and FGF-23 (Fibroblast growth factor 23) at 6 months after transplantation and treatment on each treatment group.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Percentage of patients with acute rejection at 6 months after transplantation and treatment on each treatment group.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Percentage of patients with delayed graft function at 6 months after treatment en each treatment group.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Percentage of patients with microalbuminuria on months 1, 3 and 6 post transplantation.", 
                "safety_issue": "No", 
                "time_frame": "Months 1, 3 and 6"
            }, 
            {
                "measure": "Percentage of patients on each stage of renal function on months 1, 3 and 6 post transplantation.", 
                "safety_issue": "No", 
                "time_frame": "Months 1, 3 and 6"
            }, 
            {
                "measure": "Evolution of blood pressure, speed of pulse wave, calcium-phosphorus metabolic parameters throughout the study and evolution of bone mineral density at 6 post transplantation.", 
                "safety_issue": "No", 
                "time_frame": "6 months."
            }, 
            {
                "description": "Percentage of patients with hypercalcemia  (defined as serum calcium levels > 10,3 mg/dl) on each treatment group at 6 months post transplantation.", 
                "measure": "Percentage of patients with hypercalcemia on each treatment group at 6 months post transplantation.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Evolution of anti-HLA antibodies (PRA) from basal to month 6 post-transplantation.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Frequency of adverse events or serious adverse events that occurs during the study on each treatment group.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Fundaci\u00f3n Senefro", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "AbbVie", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Effice Servicios Para la Investigacion S.L.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n Senefro", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}